Sherri Machele Donat

Summary

Affiliation: Memorial Sloan-Kettering Cancer Center
Country: USA

Publications

  1. ncbi request reprint Partial cystectomy: a contemporary review of the Memorial Sloan-Kettering Cancer Center experience and recommendations for patient selection
    Jeffrey M Holzbeierlein
    Department of Urology, Memorial Sloan Kettering Cancer Center, 353 E 68th Street, New York, NY 10021, USA
    J Urol 172:878-81. 2004
  2. ncbi request reprint Peri-operative care in patients treated for testicular cancer
    S M Donat
    Urology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Semin Surg Oncol 17:282-8. 1999
  3. ncbi request reprint Impact of body mass index on survival of patients with surgically treated renal cell carcinoma
    S Machele Donat
    Department of Urology, Memorial Sloan Kettering Cancer Center, New York, New York, USA
    J Urol 175:46-52. 2006
  4. doi request reprint Potential impact of postoperative early complications on the timing of adjuvant chemotherapy in patients undergoing radical cystectomy: a high-volume tertiary cancer center experience
    S Machele Donat
    Department of Urology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, United States
    Eur Urol 55:177-85. 2009
  5. ncbi request reprint Evaluation and follow-up strategies for superficial bladder cancer
    S Machele Donat
    Department of Urology, Memorial Sloan Kettering Cancer Center and Weill Medical College of Cornell University, 1275 York Avenue, New York, NY 10021, USA
    Urol Clin North Am 30:765-76. 2003
  6. ncbi request reprint Fluid intake and the risk of tumor recurrence in patients with superficial bladder cancer
    S Machele Donat
    Department of Urology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    J Urol 170:1777-80. 2003
  7. doi request reprint Radical cystectomy in octogenarians--does morbidity outweigh the potential survival benefits?
    S Machele Donat
    Department of Urology, the Genitourinary Oncology Service in the Department of Medicine MIM, and the Department of Epidemiology and Biostatistics AC, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
    J Urol 183:2171-7. 2010
  8. ncbi request reprint Integrating perioperative chemotherapy into the treatment of muscle-invasive bladder cancer: strategy versus reality
    S Machele Donat
    Division of Urology, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
    J Natl Compr Canc Netw 7:40-7. 2009
  9. ncbi request reprint Staged based directed surveillance of invasive bladder cancer following radical cystectomy: valuable and effective?
    S Machele Donat
    Department of Urology, Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10021, USA
    World J Urol 24:557-64. 2006
  10. ncbi request reprint Standards for surgical complication reporting in urologic oncology: time for a change
    Sherri Machele Donat
    Department of Urology, Memorial Sloan Kettering Cancer Center and Weill Medical College of Cornell University, New York, New York 10021, USA
    Urology 69:221-5. 2007

Detail Information

Publications46

  1. ncbi request reprint Partial cystectomy: a contemporary review of the Memorial Sloan-Kettering Cancer Center experience and recommendations for patient selection
    Jeffrey M Holzbeierlein
    Department of Urology, Memorial Sloan Kettering Cancer Center, 353 E 68th Street, New York, NY 10021, USA
    J Urol 172:878-81. 2004
    ..This study analyzes the outcomes of partial cystectomy in a contemporary cohort of patients to identify appropriate selection criteria for the procedure...
  2. ncbi request reprint Peri-operative care in patients treated for testicular cancer
    S M Donat
    Urology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Semin Surg Oncol 17:282-8. 1999
    ..Pre-operative evaluation and judicious fluid management have been shown to reduce the risk of life-threatening respiratory complications in the postoperative period...
  3. ncbi request reprint Impact of body mass index on survival of patients with surgically treated renal cell carcinoma
    S Machele Donat
    Department of Urology, Memorial Sloan Kettering Cancer Center, New York, New York, USA
    J Urol 175:46-52. 2006
    ..We evaluated the impact of BMI and other clinical/pathological characteristics on survival in patients with RCC treated with radical or partial nephrectomy...
  4. doi request reprint Potential impact of postoperative early complications on the timing of adjuvant chemotherapy in patients undergoing radical cystectomy: a high-volume tertiary cancer center experience
    S Machele Donat
    Department of Urology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, United States
    Eur Urol 55:177-85. 2009
    ..However, in a recent report from the National Cancer Database (NCDB), only 11.6% of stage III BCa patients received perioperative chemotherapy, the majority in the adjuvant setting...
  5. ncbi request reprint Evaluation and follow-up strategies for superficial bladder cancer
    S Machele Donat
    Department of Urology, Memorial Sloan Kettering Cancer Center and Weill Medical College of Cornell University, 1275 York Avenue, New York, NY 10021, USA
    Urol Clin North Am 30:765-76. 2003
    ..The advent and long-term success of orthotopic continent diversions has made the decision for early radical cystectomy more palatable to both the patient and physician...
  6. ncbi request reprint Fluid intake and the risk of tumor recurrence in patients with superficial bladder cancer
    S Machele Donat
    Department of Urology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    J Urol 170:1777-80. 2003
    ..High fluid intake has been associated with a decreased risk of bladder cancer development in men. We evaluated whether higher fluid intake can impact tumor recurrence rates in patients with superficial bladder cancer...
  7. doi request reprint Radical cystectomy in octogenarians--does morbidity outweigh the potential survival benefits?
    S Machele Donat
    Department of Urology, the Genitourinary Oncology Service in the Department of Medicine MIM, and the Department of Epidemiology and Biostatistics AC, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
    J Urol 183:2171-7. 2010
    ..4% of those with similar stage disease age 65 to 79 years, reflecting concern for perioperative morbidity. We evaluated the morbidity and survival outcomes of octogenarians treated with radical cystectomy at a tertiary cancer center...
  8. ncbi request reprint Integrating perioperative chemotherapy into the treatment of muscle-invasive bladder cancer: strategy versus reality
    S Machele Donat
    Division of Urology, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
    J Natl Compr Canc Netw 7:40-7. 2009
    ....
  9. ncbi request reprint Staged based directed surveillance of invasive bladder cancer following radical cystectomy: valuable and effective?
    S Machele Donat
    Department of Urology, Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10021, USA
    World J Urol 24:557-64. 2006
  10. ncbi request reprint Standards for surgical complication reporting in urologic oncology: time for a change
    Sherri Machele Donat
    Department of Urology, Memorial Sloan Kettering Cancer Center and Weill Medical College of Cornell University, New York, New York 10021, USA
    Urology 69:221-5. 2007
    ..This study analyzes the quality of complication reporting in the urologic literature...
  11. pmc A role for neoadjuvant gemcitabine plus cisplatin in muscle-invasive urothelial carcinoma of the bladder: a retrospective experience
    Atreya Dash
    Division of Urology, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Cancer 113:2471-7. 2008
    ..Gemcitabine plus cisplatin (GC) has similar efficacy and less toxicity than MVAC in metastatic disease, but is untested as neoadjuvant treatment...
  12. doi request reprint Clinical outcomes of primary bladder carcinoma in situ in a contemporary series
    Daher C Chade
    Urology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York, USA
    J Urol 184:74-80. 2010
    ..We describe patterns of disease recurrence and progression, and identify clinical outcome predictors of primary carcinoma in situ after bacillus Calmette-Guerin therapy...
  13. doi request reprint Impact of previous radiotherapy for prostate cancer on clinical outcomes of patients with bladder cancer
    David S Yee
    Urology Service, Memorial Sloan Kettering Cancer Center, New York, New York, USA
    J Urol 183:1751-6. 2010
    ..We compared the outcomes of patients with bladder cancer previously treated for prostate cancer with radiotherapy vs other treatment modalities...
  14. ncbi request reprint Prospective trial of ifosfamide, paclitaxel, and cisplatin in patients with advanced non-transitional cell carcinoma of the urothelial tract
    Matthew D Galsky
    Genitourinary Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Urology 69:255-9. 2007
    ..A unifying feature of these malignancies is their aggressive course and poor outcome with standard chemotherapeutic regimens. Given the rarity of these tumors, no prospective data are available to guide management...
  15. ncbi request reprint Impact of the number of lymph nodes retrieved on outcome in patients with muscle invasive bladder cancer
    Harry W Herr
    Departments of Urology Genitourinary Oncology Service, Medicine and Pathology, Memorial Sloan Kettering Cancer Center, New York, New York, USA
    J Urol 167:1295-8. 2002
    ..We postulate that the number of lymph nodes examined in cystectomy specimens can have an impact on the outcome of patients with bladder cancer...
  16. ncbi request reprint Significance of intraoperative ureteral evaluation at radical cystectomy for urothelial cancer
    Ganesh V Raj
    Department of Urology, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Cancer 107:2167-72. 2006
    ..In an attempt to reduce this recurrence risk, urologists employ intraoperative frozen sections to achieve an uninvolved ureteral margin. The utility of this surgical approach was examined...
  17. ncbi request reprint Defining optimal therapy for muscle invasive bladder cancer
    Harry W Herr
    Department of Urology and Genitourinary Oncology Service, Division of Solid Tumor Oncology, Memorial Sloan Kettering Cancer Center, Cornell University Weill Medical College, New York, New York 10021, USA
    J Urol 177:437-43. 2007
    ..We defined an optimal curative strategy for muscle invasive bladder cancer and to determine how best to deliver curative therapy...
  18. doi request reprint A comparison of white-light cystoscopy and narrow-band imaging cystoscopy to detect bladder tumour recurrences
    Harry W Herr
    Department of Urology, Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, New York, NY 10021, USA
    BJU Int 102:1111-4. 2008
    ....
  19. doi request reprint Age-adjusted Charlson comorbidity score is associated with treatment decisions and clinical outcomes for patients undergoing radical cystectomy for bladder cancer
    Theresa M Koppie
    Department of Urology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Cancer 112:2384-92. 2008
    ..Also evaluated was whether ACCI was associated with clinicopathologic and treatment characteristics...
  20. ncbi request reprint Natural history of positive urinary cytology after radical cystectomy
    Ganesh V Raj
    Department of Urology, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    J Urol 176:2000-5; discussion 2005. 2006
    ..The natural history and risk of disease progression in patients with positive urine cytology after radical cystectomy for urothelial carcinoma has not been adequately elucidated...
  21. ncbi request reprint Can restaging transurethral resection of T1 bladder cancer select patients for immediate cystectomy?
    Harry W Herr
    Department of Urology, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    J Urol 177:75-9; discussion 79. 2007
    ..We determined whether pathological findings on restaging transurethral resection predict early stage progression of T1 bladder cancer...
  22. doi request reprint Complications after radical and partial nephrectomy as a function of age
    William T Lowrance
    Urology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
    J Urol 183:1725-30. 2010
    ..We determined if the association of age and perioperative outcomes differed between nephrectomy types...
  23. ncbi request reprint Frequency of NY-ESO-1 and LAGE-1 expression in bladder cancer and evidence of a new NY-ESO-1 T-cell epitope in a patient with bladder cancer
    Padmanee Sharma
    Ludwig Institute for Cancer Research, New York Branch at Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Cancer Immun 3:19. 2003
    ..This patient's T-cell response was determined to be specific for a new NY-ESO-1 epitope, p94-102, in the context of HLA-B35...
  24. ncbi request reprint Efficacy of office fulguration for recurrent low grade papillary bladder tumors less than 0.5 cm
    S Machele Donat
    Department of Urology, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    J Urol 171:636-9. 2004
    ..We report our experience with office fulguration of small, recurrent, low grade papillary tumors using flexible cystodiathermy...
  25. ncbi request reprint Bladder cancer as a prognostic factor for upper tract transitional cell carcinoma
    Michael Mullerad
    Department of Urology, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    J Urol 172:2177-81. 2004
    ..Overall 5-year disease specific survival is in the range of 16.5% to 95% depending on stage. In this study we evaluated predictors associated with disease recurrence and disease specific survival...
  26. doi request reprint Clinical outcome in a contemporary series of restaged patients with clinical T1 bladder cancer
    Guido Dalbagni
    Division of Urology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Eur Urol 56:903-10. 2009
    ..To evaluate the indications for early and deferred cystectomy and to report the impact of this tailored approach on survival...
  27. ncbi request reprint A re-staging transurethral resection predicts early progression of superficial bladder cancer
    Harry W Herr
    Department of Urology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    BJU Int 97:1194-8. 2006
    ..To determine whether pathology on a re-staging transurethral resection (TUR) predicts the early progression of superficial bladder cancer...
  28. ncbi request reprint Clinical characteristics of bladder cancer in patients previously treated with radiation for prostate cancer
    Jaspreet S Sandhu
    Department of Urology, Memorial Sloan Kettering Cancer Center and Weill Medical College of Cornell University, New York, NY, USA
    BJU Int 98:59-62. 2006
    ....
  29. doi request reprint Placement of transileal conduit retrograde nephroureteral stents in patients with ureteral obstruction after cystectomy: technique and outcome
    William Alago
    Division of Interventional Radiology and Image Guided Therapy, Department of Radiology, Memorial Sloan Kettering Cancer Center, 1275 York Ave, Ste H118, New York, NY 10021, USA
    AJR Am J Roentgenol 191:1536-9. 2008
    ..The objective of our article is to describe the technique, complications, and long-term results of transileal conduit retrograde nephroureteral stents placed for ureteral obstruction after radical cystectomy...
  30. ncbi request reprint Management of low grade papillary bladder tumors
    Harry W Herr
    Department of Urology, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    J Urol 178:1201-5; discussion 1205. 2007
    ..We evaluated the management and treatment outcomes of low grade papillary bladder tumors...
  31. ncbi request reprint Correlation of cystoscopy with histology of recurrent papillary tumors of the bladder
    Harry W Herr
    Department of Urology, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    J Urol 168:978-80. 2002
    ....
  32. ncbi request reprint Orthotopic urinary diversion after cystectomy for bladder cancer: implications for cancer control and patterns of disease recurrence
    Ofer Yossepowitch
    Department of Urology, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    J Urol 169:177-81. 2003
    ..The impact of orthotopic urinary diversion on the quality of cystectomy and ensuing cancer control has not been adequately studied. We analyzed our experience with this clinical problem...
  33. doi request reprint Clinical outcome of primary versus secondary bladder carcinoma in situ
    Daher C Chade
    Urology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
    J Urol 184:464-9. 2010
    ..Differences in clinical outcome are still unclear between primary and secondary bladder carcinoma in situ. We compared the clinical outcomes of primary and secondary carcinoma in situ, and identified predictive factors...
  34. ncbi request reprint Risk assessment of prostatic pathology in patients undergoing radical cystoprostatectomy
    Joseph A Pettus
    Department of Urology, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Eur Urol 53:370-5. 2008
    ....
  35. ncbi request reprint Early nasogastric tube removal combined with metoclopramide after postchemotherapy retroperitoneal lymph node dissection for metastatic testicular nonseminomatous germ cell tumor
    John W Davis
    Department of Urology, University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Urology 59:579-83. 2002
    ..To evaluate the efficacy of combining early nasogastric tube (NGT) removal and metoclopramide after postchemotherapy retroperitoneal lymph node dissection (RPLND) in decreasing complications, time to diet tolerance, and discharge...
  36. ncbi request reprint Feasibility of radical prostatectomy after neoadjuvant chemohormonal therapy for patients with high risk or locally advanced prostate cancer: results of a phase I/II study
    Badrinath R Konety
    Department of Urology, Memorial Sloan Kettering Cancer Center and Cornell University, New York, New York 10021, USA
    J Urol 171:709-13. 2004
    ....
  37. ncbi request reprint Safety and efficacy of intravesical bacillus Calmette-Guerin instillations in steroid treated and immunocompromised patients
    Ofer Yossepowitch
    Department of Urology, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    J Urol 176:482-5. 2006
    ..We assessed the safety and efficacy of intravesical bacillus Calmette-Guerin instillations in steroid treated and immunocompromised patients...
  38. ncbi request reprint Does body mass index affect survival of patients undergoing radical or partial cystectomy for bladder cancer?
    Jason Hafron
    Department of Urology, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    J Urol 173:1513-7. 2005
    ..Obesity is estimated to account for up to 20% of all cancer deaths. We evaluated the effect of body mass index (BMI) on survival in patients undergoing radical or partial cystectomy for bladder cancer...
  39. pmc Obesity is associated with a higher risk of clear-cell renal cell carcinoma than with other histologies
    William T Lowrance
    Department of Surgery, Urology Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    BJU Int 105:16-20. 2010
    ....
  40. ncbi request reprint Longitudinal risk of upper tract recurrence following radical cystectomy for urothelial cancer and the potential implications for long-term surveillance
    William Tran
    Department of Urology, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    J Urol 179:96-100. 2008
    ..However, these recurrence rates are based on statistical methodology that does not take censoring into account. We used landmark time analysis to determine whether the risk of upper tract recurrence changes over time...
  41. ncbi request reprint Formulas calculating creatinine clearance are inadequate for determining eligibility for Cisplatin-based chemotherapy in bladder cancer
    Ganesh V Raj
    Department of Urology, 353 E 68th St, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Clin Oncol 24:3095-100. 2006
    ..We hypothesize these formulas may underestimate measured CrCl, and therefore the eligibility for cisplatin-based chemotherapy...
  42. ncbi request reprint Association between urinary cytology and pathology for nontransitional cell malignancies of the urinary tract
    Ganesh V Raj
    Department of Urology, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    J Urol 175:2038-41; discussion 2041. 2006
    ..Because nontransitional cell carcinoma neoplasms of the urinary tract are rare in Western countries, we examined the association between urinary cytology and pathology evaluations for these tumors...
  43. ncbi request reprint Perioperative clinical thromboembolic events after radical or partial nephrectomy
    Joseph A Pettus
    Department of Urology, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Urology 68:988-92. 2006
    ..Cancer is an established risk factor for deep vein thrombosis (DVT) and pulmonary embolism (PE); however, their incidence after nephrectomy for renal tumors has been poorly studied...
  44. ncbi request reprint Urinary diversion: options, patient selection, and outcomes
    Dipen J Parekh
    Department of Urology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Semin Oncol 34:98-109. 2007
    ....
  45. doi request reprint Analysis of gender differences in early perioperative complications following radical cystectomy at a tertiary cancer center using a standardized reporting methodology
    Timothy Siegrist
    Department of Urology, Memorial Sloan Kettering Cancer, New York, NY 10021, USA
    Urol Oncol 28:112-7. 2010
    ..Variability in reporting methodologies may affect findings; therefore, we utilized a standardized reporting methodology to evaluate for gender differences in perioperative complications at a tertiary cancer center...
  46. ncbi request reprint Use of urinary biomarkers for bladder cancer surveillance: patient perspectives
    Ofer Yossepowitch
    Department of Urology, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    J Urol 177:1277-82; discussion 1282. 2007
    ..We assessed whether patients would accept a urine biomarker assay over flexible cystoscopy for monitoring bladder cancer...